Management of Cardiogenic Pulmonary Edema (RENAU-OAP) (RENAU-OAP)

June 14, 2019 updated by: Centre Hospitalier Annecy Genevois

Evaluation of Professional Practices on the Management of Cardiogenic Pulmonary Edema (RENAU-OAP)

The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to french disability-health surveys. In France, more than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in many cancers. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.

The severity of cardiogenic pulmonary edema depends on several factors such as etiology, hemodynamic status, effect on hematosis, and fatigue.

It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.

The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating guidelines on cardiogenic pulmonary edema management which will then be assessed.

Study Overview

Detailed Description

The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to disability-health surveys in France. In recent years, effective treatments (revascularization in percutaneous coronary intervention, circulatory assistance) helped reduce mortality in post-myocardial infarction, which combined with the increase of life expectancy has led to an increase number of patients with chronic heart failure. More than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in cancers of the breast, bladder, colon, ovarian, and prostate. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.

Main clinical manifestations are those of left heart failure, such as cardiogenic pulmonary edema which is a medical emergency. Treatment must take into account pathophysiological aspects of heart failure, etiologies of cardiogenic pulmonary edema and any potential factors or triggers apart from general measures. Two consensus statements and an international recommendation help define therapeutic strategies in this particular situation.

Signs suggestive of cardiogenic pulmonary edema include orthopnea, bilateral crackles or wheezing (patients over 70 years without known asthma), edema of the lower limbs, and gallop sound on heart auscultation. The evolution of these signs makes it particularly possible to manage the response to the treatment. The severity of cardiogenic pulmonary edema depends on several factors such as etiology (ECG analysis and chest pain assessment for acute coronary syndrome), hemodynamic status (blood pressure, heart rate), effect on hematosis (cyanosis, oxygen saturation), and fatigue (low respiratory rate with persistent cardiogenic pulmonary edema signs). The respiratory rate represents a simple clinical feature that can be used to quantify dyspnea (sign of severity if greater than 30 per minute in adults) and then follow its evolution (improvement, exhaustion). Disorders of consciousness can testify to the severity of the hemodynamic state and/or exhaustion.

Cardiogenic pulmonary edema management without shock implies urgent administration of vasodilators (trinitrin) and intravenous loop diuretics in presence of congestion signs along with the establishment of a system of care adapted to severity (Emergency Mobile Services or ambulance, hospitalization in Intensive Care Unit, intensive cardiology unit, cardiology or medicine department, or emergency passage). The subsequent therapeutic management will especially depend on initial treatment by the primary care physician, so it is preferable to record doses and hours of medications. Non-hospitalization must remain exceptional for non-severe decompensation with rapidly favorable evolution.

The French Observatory of Acute Heart Failure (OFICA) including nearly 1,800 patients specified epidemiological and therapeutic data of patients hospitalized for cardiogenic pulmonary edema in 2009. However, this study did not describe the initial management of the Mobile Emergency and Resuscitation Service and emergency services of hospitals. It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.

The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute-Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating a guideline on cardiogenic pulmonary edema management which will then be assessed.

Study Type

Observational

Enrollment (Actual)

859

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Pringy, France, F-74374
        • Ch Annecy Genevois

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

As the goal of this study is to analyze common practices, data from the french medicalized information system program will be used to select a study population as exhaustive as possible.

This program is dedicated to systematic collection of data from hospital stays. Each hospital stay is identified by a unique number and a diagnosis is attributed for each, at the end of every hospital stay. Diagnosis are based on the International Classification of Diseases (ICD-10). At hospital levels, a unique stay number can be related to names and addresses of involved patients.

French medicalized information system program data are analyzed at a regional and then a national level.

For this study, cases will be screened if they had a I500, I501 and I509 ICD-10 diagnosis (main or associated).

Description

Inclusion Criteria:

  • ≥18 years old
  • hospitalization during one of the two designed period (either year 2013, or year 2017) in a center belonging to Northern French Alps Emergency Network
  • diagnosis of cardiogenic pulmonary edema, or heart failure (either left-sided, congestive or unspecified)

Exclusion Criteria:

  • people who refuse to have their health information used will not be included
  • people whose care will have begun in a center not belonging to the Northern French Alps Emergency Network

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Baseline care
Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
Referential's dissemination
Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of quality of initial care of patients with cardiogenic pulmonary edema after dissemination of good practice standards
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Two kinds of predefined quality indicators will be evaluated at different stages of care and compared among the two periods, before and after dissemination of good practice standards, looking for informations in medical charts during the management of patients either care by Mobile Emergency and Resuscitation Services or at emergency departments and in mails at time of hospital discharge).
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients' description at the onset of cardiogenic pulmonary edema (clinical)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Clinical characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Patients' description at the onset of cardiogenic pulmonary edema (biological)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Biological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Patients' description at the onset of cardiogenic pulmonary edema (radiological)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Radiological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Patients' description at the onset of cardiogenic pulmonary edema (echocardiographic)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Echocardiographic characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Mortality of patients hospitalized for cardiogenic pulmonary edema
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
number of patients dying during hospitalization for cardiogenic pulmonary edema
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Needs for Hospitalization in intensive care units
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
number (and rate) of patients with cardiogenic pulmonary edema, requiring hospitalization in intensive care unit
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Needs for respiratory assistance
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
number of patients and kind of respiratory assistance for patients with cardiogenic pulmonary edema
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Inter-services transfers
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
number of patients who require transfers from an emergency room (or a cardiology ward) to intensive care units and vice-versa
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Length of stay in hospital
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
number of days between arrival and discharge
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
Re-hospitalizations during the first six months
Time Frame: up to six months
number of re-hospitalizations during the first six months after the onset of cardiogenic pulmonary edema
up to six months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Loic BELLE, MD, Centre Hospitalier Annecy Genevois

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2015

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

May 2, 2017

First Submitted That Met QC Criteria

May 9, 2017

First Posted (Actual)

May 11, 2017

Study Record Updates

Last Update Posted (Actual)

June 18, 2019

Last Update Submitted That Met QC Criteria

June 14, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyspnea, Paroxysmal

Clinical Trials on Baseline care

3
Subscribe